2. Biochemical recurrence

- GUH - A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
- HUH - Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy
- JHMI E2809 Phase II, Randomized Study of MK-2206 Bicalutamide Combination in Patients with Rising PSA at High-Risk of Progression After Primary Therapy
- JHMI J1161: Phase I and II Study of Safety and Efficacy of Muscadine Plus, MPX, in Men with Prostate Cancer- A Randomized Dose-Finding Study of 2 Doses of MPX on Rising PSA following Initial Therapy
- JHMI J1307 A phase 2, randomized, 3-arm study of abiraterone acetate alone, AA plus degarelix, a GnRH antagonist, and degarelix alone for patients with prostate cancer with a rising PSA or a rising PSA and nodal disease following definitive radical prostatectomy
- JHMI J1298 Phase II Study of Bipolar Androgen-based Therapy for Men with Androgen Ablation Naive Recurrent Prostate Cancer
- NCI 07-C-0107: A randomized Phase II trial combining vaccine therapy with PROSTVAC-TRICOM and Flutamide, vs Flutamide alone in men with androgen insensitive, non metastatic (D0.5) prostate cancer.